{
  "claims": [
    {
      "gaap_classification": "non_gaap",
      "claimed_value": 4.6,
      "is_approximate": false,
      "period": "Q2 2025",
      "metric_context": "Total",
      "speaker_role": "ceo",
      "metric_type": "revenue",
      "speaker": "Joaquin Duato",
      "claim_type": "yoy_growth",
      "quote_end_char": 1069,
      "claim_id": "claim_001",
      "comparison_period": "Q2 2024",
      "qualifiers": [
        "operational"
      ],
      "claimed_value_raw": "4.6%",
      "confidence": 1,
      "scale": null,
      "quote_start_char": 1001,
      "quote_text": "In the second quarter, we delivered operational sales growth of 4.6%",
      "unit": "percent"
    },
    {
      "unit": "percent",
      "claimed_value_raw": "3.8%",
      "claim_id": "claim_002",
      "quote_start_char": 1091,
      "scale": null,
      "quote_end_char": 1156,
      "quote_text": "In innovative medicine, we reported 3.8% operational sales growth",
      "comparison_period": "Q2 2024",
      "metric_type": "revenue",
      "is_approximate": false,
      "metric_context": "Innovative Medicine",
      "claimed_value": 3.8,
      "confidence": 1,
      "speaker": "Joaquin Duato",
      "period": "Q2 2025",
      "claim_type": "yoy_growth",
      "qualifiers": [
        "operational"
      ],
      "gaap_classification": "non_gaap",
      "speaker_role": "ceo"
    },
    {
      "metric_context": "Innovative Medicine",
      "qualifiers": [
        "more than",
        "record",
        "first time"
      ],
      "claim_id": "claim_003",
      "comparison_period": null,
      "metric_type": "revenue",
      "quote_end_char": 1229,
      "quote_start_char": 1158,
      "gaap_classification": "gaap",
      "speaker_role": "ceo",
      "claimed_value": 15,
      "unit": "dollars",
      "claimed_value_raw": "$15 billion",
      "claim_type": "absolute",
      "speaker": "Joaquin Duato",
      "quote_text": "delivering more than $15 billion in quarterly sales for the first time.",
      "period": "Q2 2025",
      "scale": "billions",
      "confidence": 1,
      "is_approximate": false
    },
    {
      "comparison_period": "Q2 2024",
      "quote_text": "Delivering 6.1% operational sales growth",
      "quote_end_char": 1667,
      "claimed_value": 6.1,
      "claimed_value_raw": "6.1%",
      "quote_start_char": 1627,
      "period": "Q2 2025",
      "speaker": "Joaquin Duato",
      "gaap_classification": "non_gaap",
      "claim_id": "claim_004",
      "speaker_role": "ceo",
      "unit": "percent",
      "claim_type": "yoy_growth",
      "metric_context": "MedTech",
      "scale": null,
      "metric_type": "revenue",
      "is_approximate": false,
      "qualifiers": [
        "operational"
      ],
      "confidence": 1
    },
    {
      "quote_start_char": 1791,
      "quote_end_char": 1857,
      "is_approximate": false,
      "quote_text": "we are pleased to raise our full-year sales guidance by $2 billion",
      "period": "FY 2025",
      "metric_type": "revenue",
      "speaker": "Joaquin Duato",
      "claim_type": "guidance",
      "unit": "dollars",
      "metric_context": "Total",
      "claimed_value_raw": "$2 billion",
      "speaker_role": "ceo",
      "claim_id": "claim_005",
      "scale": "billions",
      "confidence": 1,
      "claimed_value": 2,
      "qualifiers": [
        "raise"
      ],
      "comparison_period": null,
      "gaap_classification": "gaap"
    },
    {
      "claim_type": "guidance",
      "quote_start_char": 1858,
      "metric_context": "Total",
      "is_approximate": false,
      "speaker_role": "ceo",
      "period": "FY 2025",
      "gaap_classification": "non_gaap",
      "scale": null,
      "claim_id": "claim_006",
      "qualifiers": [
        "raise"
      ],
      "quote_end_char": 1883,
      "quote_text": "and EPS guidance by $0.25",
      "speaker": "Joaquin Duato",
      "confidence": 1,
      "comparison_period": null,
      "metric_type": "eps_diluted",
      "claimed_value_raw": "$0.25",
      "claimed_value": 0.25,
      "unit": "per_share"
    },
    {
      "quote_text": "10.60",
      "claimed_value": 10.6,
      "unit": "per_share",
      "quote_start_char": 1890,
      "confidence": 1,
      "comparison_period": null,
      "claim_id": "claim_007",
      "speaker_role": "ceo",
      "quote_end_char": 1895,
      "metric_type": "eps_diluted",
      "gaap_classification": "non_gaap",
      "claimed_value_raw": "$10.60",
      "claim_type": "guidance",
      "scale": null,
      "qualifiers": [],
      "speaker": "Joaquin Duato",
      "metric_context": "Total",
      "is_approximate": false,
      "period": "FY 2025"
    },
    {
      "speaker_role": "ceo",
      "quote_text": "10.85.",
      "metric_type": "eps_diluted",
      "claimed_value_raw": "$10.85",
      "scale": null,
      "comparison_period": null,
      "speaker": "Joaquin Duato",
      "unit": "per_share",
      "period": "FY 2025",
      "gaap_classification": "non_gaap",
      "quote_end_char": 1906,
      "metric_context": "Total",
      "quote_start_char": 1900,
      "qualifiers": [
        "to"
      ],
      "confidence": 1,
      "claim_id": "claim_008",
      "is_approximate": false,
      "claimed_value": 10.85,
      "claim_type": "guidance"
    },
    {
      "metric_context": "Oncology",
      "speaker_role": "ceo",
      "scale": "billions",
      "gaap_classification": "gaap",
      "claim_id": "claim_009",
      "comparison_period": null,
      "speaker": "Joaquin Duato",
      "unit": "dollars",
      "claimed_value": 50,
      "quote_text": "we expect to become the number one oncology company by 2030 with sales of more than $50 billion.",
      "period": "FY 2030",
      "confidence": 1,
      "metric_type": "revenue",
      "is_approximate": false,
      "claimed_value_raw": "$50 billion",
      "quote_end_char": 3012,
      "claim_type": "guidance",
      "quote_start_char": 2916,
      "qualifiers": [
        "more than"
      ]
    },
    {
      "qualifiers": [
        "operational"
      ],
      "period": "Q2 2025",
      "claim_id": "claim_010",
      "claimed_value_raw": "22.3%",
      "speaker_role": "ceo",
      "speaker": "Joaquin Duato",
      "metric_type": "revenue",
      "comparison_period": "Q2 2024",
      "quote_start_char": 3013,
      "metric_context": "Oncology",
      "quote_text": "And when you look at our quarterly results in oncology, with operational sales growth of 22.3%",
      "claimed_value": 22.3,
      "claim_type": "yoy_growth",
      "quote_end_char": 3107,
      "confidence": 1,
      "gaap_classification": "non_gaap",
      "scale": null,
      "unit": "percent",
      "is_approximate": false
    },
    {
      "speaker": "Joaquin Duato",
      "gaap_classification": "gaap",
      "claim_type": "guidance",
      "confidence": 1,
      "comparison_period": null,
      "qualifiers": [
        "peak year",
        "at least",
        "annual"
      ],
      "claimed_value_raw": "$5 billion",
      "speaker_role": "ceo",
      "quote_start_char": 4724,
      "period": "Peak Year",
      "metric_type": "revenue",
      "unit": "dollars",
      "quote_text": "We expect TAR-200 to generate at least $5 billion in annual peak year sales.",
      "scale": "billions",
      "quote_end_char": 4800,
      "is_approximate": false,
      "claimed_value": 5,
      "metric_context": "TAR-200",
      "claim_id": "claim_011"
    },
    {
      "unit": "percent",
      "claimed_value_raw": "30%",
      "qualifiers": [],
      "scale": null,
      "quote_text": "TREMFYA grew 30% in the quarter.",
      "claimed_value": 30,
      "metric_type": "revenue",
      "metric_context": "TREMFYA",
      "claim_id": "claim_012",
      "quote_start_char": 5500,
      "claim_type": "yoy_growth",
      "comparison_period": "Q2 2024",
      "confidence": 1,
      "quote_end_char": 5532,
      "is_approximate": false,
      "speaker_role": "ceo",
      "speaker": "Joaquin Duato",
      "period": "Q2 2025",
      "gaap_classification": "gaap"
    },
    {
      "metric_type": "revenue",
      "metric_context": "TREMFYA",
      "speaker_role": "ceo",
      "quote_text": "we expect TREMFYA to generate at least $10 billion annually in peak year sales.",
      "qualifiers": [
        "at least",
        "annually"
      ],
      "claim_id": "claim_013",
      "scale": "billions",
      "comparison_period": null,
      "unit": "dollars",
      "claimed_value_raw": "$10 billion",
      "speaker": "Joaquin Duato",
      "period": "Peak Year",
      "confidence": 1,
      "is_approximate": false,
      "quote_end_char": 5674,
      "quote_start_char": 5595,
      "claim_type": "guidance",
      "claimed_value": 10,
      "gaap_classification": "gaap"
    },
    {
      "unit": "percent",
      "metric_context": "SPRAVATO",
      "comparison_period": "Q2 2024",
      "claim_type": "yoy_growth",
      "period": "Q2 2025",
      "confidence": 1,
      "metric_type": "revenue",
      "claimed_value": 53,
      "claim_id": "claim_014",
      "is_approximate": false,
      "scale": null,
      "gaap_classification": "gaap",
      "speaker": "Joaquin Duato",
      "claimed_value_raw": "53%",
      "quote_end_char": 6364,
      "speaker_role": "ceo",
      "qualifiers": [],
      "quote_start_char": 6340,
      "quote_text": "In Q2, SPRAVATO grew 53%"
    },
    {
      "claim_type": "guidance",
      "claimed_value_raw": "$5 billion-plus",
      "is_approximate": false,
      "confidence": 1,
      "gaap_classification": "gaap",
      "speaker_role": "ceo",
      "period": "Peak Year",
      "metric_type": "revenue",
      "quote_start_char": 6934,
      "metric_context": "CAPLYTA",
      "scale": "billions",
      "claimed_value": 5,
      "quote_end_char": 7046,
      "quote_text": "CAPLYTA adds to Johnson & Johnson's robust lineup of therapies with $5 billion-plus potential in peak year sales",
      "speaker": "Joaquin Duato",
      "unit": "dollars",
      "claim_id": "claim_015",
      "comparison_period": null,
      "qualifiers": [
        "potential"
      ]
    },
    {
      "quote_start_char": 7398,
      "scale": null,
      "claimed_value_raw": "22%",
      "claim_type": "yoy_growth",
      "speaker": "Joaquin Duato",
      "metric_type": "revenue",
      "qualifiers": [
        "operational",
        "over"
      ],
      "confidence": 1,
      "speaker_role": "ceo",
      "quote_text": "In Q2, we delivered over 22% operational sales growth over the quarter",
      "claimed_value": 22,
      "unit": "percent",
      "gaap_classification": "non_gaap",
      "comparison_period": "Q2 2024",
      "period": "Q2 2025",
      "metric_context": "Cardiovascular",
      "is_approximate": false,
      "quote_end_char": 7468,
      "claim_id": "claim_016"
    },
    {
      "qualifiers": [
        "operational",
        "close to"
      ],
      "quote_start_char": 7808,
      "claim_type": "yoy_growth",
      "quote_end_char": 7906,
      "speaker_role": "ceo",
      "quote_text": "First is electrophysiology, which delivered close to 10% operational sales growth over the quarter",
      "claimed_value_raw": "10%",
      "confidence": 1,
      "claim_id": "claim_017",
      "gaap_classification": "non_gaap",
      "speaker": "Joaquin Duato",
      "is_approximate": true,
      "scale": null,
      "claimed_value": 10,
      "metric_type": "revenue",
      "metric_context": "Electrophysiology",
      "period": "Q2 2025",
      "comparison_period": "Q2 2024",
      "unit": "percent"
    },
    {
      "metric_type": "revenue",
      "period": "FY 2025",
      "quote_start_char": 8711,
      "gaap_classification": "gaap",
      "claimed_value": 13,
      "claim_type": "guidance",
      "is_approximate": false,
      "confidence": 1,
      "claimed_value_raw": "$13 billion",
      "qualifiers": [],
      "comparison_period": null,
      "unit": "dollars",
      "claim_id": "claim_018",
      "speaker_role": "ceo",
      "metric_context": "Shockwave",
      "speaker": "Joaquin Duato",
      "scale": "billions",
      "quote_text": "Shockwave is expected to be our $13 billion MedTech platform by the end of the year",
      "quote_end_char": 8794
    },
    {
      "quote_start_char": 10314,
      "claim_id": "claim_019",
      "unit": "percent",
      "quote_end_char": 10337,
      "claimed_value": 8.9,
      "speaker_role": "ceo",
      "is_approximate": false,
      "scale": null,
      "confidence": 1,
      "gaap_classification": "non_gaap",
      "comparison_period": "Q2 2024",
      "qualifiers": [],
      "metric_type": "revenue",
      "metric_context": "Surgical Vision",
      "claimed_value_raw": "8.9%",
      "speaker": "Joaquin Duato",
      "quote_text": "8.9% in Surgical Vision",
      "period": "Q2 2025",
      "claim_type": "yoy_growth"
    },
    {
      "qualifiers": [],
      "gaap_classification": "gaap",
      "speaker": "Darren Snellgrove",
      "quote_text": "Worldwide sales were $23.7 billion for the quarter.",
      "metric_context": "Total",
      "is_approximate": false,
      "comparison_period": null,
      "scale": "billions",
      "claimed_value_raw": "$23.7 billion",
      "metric_type": "revenue",
      "speaker_role": "management",
      "quote_end_char": 11620,
      "quote_start_char": 11569,
      "claim_id": "claim_020",
      "claim_type": "absolute",
      "period": "Q2 2025",
      "unit": "dollars",
      "confidence": 1,
      "claimed_value": 23.7
    },
    {
      "unit": "percent",
      "is_approximate": false,
      "speaker_role": "management",
      "claim_type": "yoy_growth",
      "confidence": 1,
      "claim_id": "claim_021",
      "metric_type": "revenue",
      "quote_end_char": 11704,
      "comparison_period": "Q2 2024",
      "metric_context": "Total",
      "speaker": "Darren Snellgrove",
      "claimed_value": 4.6,
      "scale": null,
      "gaap_classification": "gaap",
      "period": "Q2 2025",
      "quote_text": "Sales increased 4.6% despite an approximate 710 basis point headwind from STELARRA.",
      "quote_start_char": 11621,
      "qualifiers": [],
      "claimed_value_raw": "4.6%"
    },
    {
      "claimed_value": 7.8,
      "comparison_period": "Q2 2024",
      "quote_end_char": 11730,
      "speaker_role": "management",
      "metric_type": "revenue",
      "metric_context": "US",
      "quote_text": "Growth in the US was 7.8%",
      "claimed_value_raw": "7.8%",
      "speaker": "Darren Snellgrove",
      "claim_id": "claim_022",
      "is_approximate": false,
      "period": "Q2 2025",
      "qualifiers": [],
      "scale": null,
      "confidence": 1,
      "unit": "percent",
      "claim_type": "yoy_growth",
      "quote_start_char": 11705,
      "gaap_classification": "gaap"
    },
    {
      "is_approximate": false,
      "speaker": "Darren Snellgrove",
      "claim_id": "claim_023",
      "unit": "percent",
      "qualifiers": [],
      "speaker_role": "management",
      "quote_end_char": 11758,
      "metric_type": "revenue",
      "claimed_value_raw": "0.6%",
      "scale": null,
      "metric_context": "Outside of the US",
      "period": "Q2 2025",
      "comparison_period": "Q2 2024",
      "confidence": 1,
      "quote_start_char": 11731,
      "claimed_value": 0.6,
      "quote_text": "and 0.6% outside of the US.",
      "claim_type": "yoy_growth",
      "gaap_classification": "gaap"
    },
    {
      "period": "Q2 2025",
      "comparison_period": null,
      "qualifiers": [],
      "quote_start_char": 11908,
      "claim_id": "claim_024",
      "unit": "dollars",
      "scale": "billions",
      "speaker_role": "management",
      "confidence": 1,
      "gaap_classification": "gaap",
      "metric_context": "Total",
      "claim_type": "absolute",
      "metric_type": "net_income",
      "quote_end_char": 11955,
      "claimed_value": 5.5,
      "claimed_value_raw": "$5.5 billion",
      "is_approximate": false,
      "quote_text": "For the quarter, net earnings were $5.5 billion",
      "speaker": "Darren Snellgrove"
    },
    {
      "gaap_classification": "gaap",
      "confidence": 1,
      "qualifiers": [],
      "metric_context": "Total",
      "claim_id": "claim_025",
      "claimed_value_raw": "$2.29",
      "unit": "per_share",
      "period": "Q2 2025",
      "is_approximate": false,
      "quote_text": "with diluted earnings per share of $2.29",
      "claim_type": "absolute",
      "speaker_role": "management",
      "speaker": "Darren Snellgrove",
      "metric_type": "eps_diluted",
      "quote_end_char": 11996,
      "scale": null,
      "comparison_period": null,
      "quote_start_char": 11956,
      "claimed_value": 2.29
    },
    {
      "qualifiers": [],
      "period": "Q2 2024",
      "quote_start_char": 11997,
      "comparison_period": null,
      "unit": "per_share",
      "claimed_value": 1.93,
      "claimed_value_raw": "$1.93",
      "claim_type": "absolute",
      "speaker_role": "management",
      "confidence": 1,
      "speaker": "Darren Snellgrove",
      "claim_id": "claim_026",
      "is_approximate": false,
      "gaap_classification": "gaap",
      "metric_type": "eps_diluted",
      "metric_context": "Total",
      "quote_text": "versus diluted earnings per share of $1.93 a year ago.",
      "scale": null,
      "quote_end_char": 12051
    },
    {
      "metric_context": "Total",
      "quote_end_char": 12108,
      "quote_start_char": 12053,
      "qualifiers": [
        "adjusted"
      ],
      "period": "Q2 2025",
      "is_approximate": false,
      "speaker_role": "management",
      "quote_text": "Adjusted net earnings for the quarter were $6.7 billion",
      "scale": "billions",
      "metric_type": "net_income",
      "claimed_value": 6.7,
      "confidence": 1,
      "comparison_period": null,
      "claimed_value_raw": "$6.7 billion",
      "speaker": "Darren Snellgrove",
      "claim_type": "absolute",
      "gaap_classification": "non_gaap",
      "unit": "dollars",
      "claim_id": "claim_027"
    },
    {
      "claim_type": "absolute",
      "quote_text": "with adjusted diluted earnings per share of $2.77",
      "metric_type": "eps_diluted",
      "comparison_period": null,
      "claimed_value_raw": "$2.77",
      "quote_end_char": 12158,
      "scale": null,
      "confidence": 1,
      "gaap_classification": "non_gaap",
      "unit": "per_share",
      "speaker": "Darren Snellgrove, speaker_role: management",
      "quote_start_char": 12109,
      "qualifiers": [
        "adjusted"
      ],
      "claimed_value": 2.77,
      "period": "Q2 2025",
      "claim_id": "claim_028",
      "metric_context": "Total",
      "is_approximate": false
    },
    {
      "comparison_period": "Q2 2024",
      "confidence": 1,
      "metric_type": "eps_diluted",
      "claim_id": "claim_029",
      "quote_start_char": 12192,
      "claim_type": "yoy_growth",
      "metric_context": "Total (Adjusted EPS)",
      "qualifiers": [
        "decrease"
      ],
      "is_approximate": false,
      "speaker": "Darren Snellgrove",
      "speaker_role": "management",
      "quote_end_char": 12254,
      "unit": "percent",
      "gaap_classification": "non_gaap",
      "claimed_value_raw": "1.8%",
      "claimed_value": 1.8,
      "quote_text": "and 1.8% respectively, compared to the second quarter of 2024.",
      "period": "Q2 2025",
      "scale": null
    },
    {
      "speaker": "Darren Snellgrove",
      "claim_type": "absolute",
      "claim_id": "claim_030",
      "quote_start_char": 12693,
      "quote_text": "Worldwide sales of $15.2 billion increased 3.8% despite an approximate 1170 basis point headwind from STELARRA",
      "speaker_role": "management",
      "comparison_period": null,
      "quote_end_char": 12803,
      "gaap_classification": "gaap",
      "claimed_value_raw": "$15.2 billion",
      "metric_context": "Innovative Medicine",
      "scale": "billions",
      "claimed_value": 15.2,
      "metric_type": "revenue",
      "confidence": 1,
      "period": "Q2 2025",
      "is_approximate": false,
      "qualifiers": [],
      "unit": "dollars"
    },
    {
      "is_approximate": false,
      "scale": null,
      "claim_id": "claim_031",
      "speaker": "Darren Snellgrove",
      "claimed_value": 21.5,
      "speaker_role": "management",
      "qualifiers": [],
      "quote_end_char": 13219,
      "metric_context": "DARZALEX",
      "quote_text": "DARZALEX growth was 21.5%",
      "quote_start_char": 13194,
      "unit": "percent",
      "claim_type": "yoy_growth",
      "claimed_value_raw": "21.5%",
      "confidence": 1,
      "gaap_classification": "gaap",
      "period": "Q2 2025",
      "comparison_period": "Q2 2024",
      "metric_type": "revenue"
    },
    {
      "unit": "dollars",
      "claimed_value_raw": "$439 million",
      "quote_start_char": 13402,
      "period": "Q2 2025",
      "scale": "millions",
      "speaker": "Darren Snellgrove",
      "metric_type": "revenue",
      "comparison_period": null,
      "claim_id": "claim_032",
      "speaker_role": "management",
      "claimed_value": 439,
      "quote_text": "CARVICTI achieved sales of $439 million with growth of over 100%",
      "qualifiers": [],
      "metric_context": "CARVICTI",
      "confidence": 1,
      "claim_type": "absolute",
      "quote_end_char": 13466,
      "is_approximate": false,
      "gaap_classification": "gaap"
    },
    {
      "period": "Q2 2025",
      "metric_type": "revenue",
      "claim_id": "claim_033,claim_type: qoq_growth",
      "qualifiers": [
        "sequential growth"
      ],
      "is_approximate": false,
      "speaker_role": "management",
      "quote_text": "This reflects continued strong sequential growth of 17.9%",
      "claim_type": "qoq_growth",
      "comparison_period": "Q1 2025",
      "confidence": 1,
      "unit": "percent",
      "metric_context": "CARVICTI",
      "quote_end_char": 13571,
      "gaap_classification": "gaap",
      "claimed_value_raw": "17.9%",
      "scale": null,
      "speaker": "Darren Snellgrove",
      "quote_start_char": 13514,
      "claimed_value": 17.9
    },
    {
      "qualifiers": [],
      "quote_text": "RYBREVANT plus LUMAKRAS delivered sales of $179 million and growth over 100%",
      "period": "Q2 2025",
      "claim_type": "absolute",
      "comparison_period": null,
      "gaap_classification": "gaap",
      "claimed_value": 179,
      "speaker_role": "management",
      "is_approximate": false,
      "quote_start_char": 13934,
      "quote_end_char": 14010,
      "metric_type": "revenue",
      "claimed_value_raw": "$179 million",
      "unit": "dollars",
      "scale": "millions",
      "claim_id": "claim_034",
      "confidence": 1,
      "metric_context": "RYBREVANT plus LUMAKRAS",
      "speaker": "Darren Snellgrove"
    },
    {
      "metric_context": "TREMFYA",
      "speaker": "Darren Snellgrove",
      "gaap_classification": "gaap",
      "claim_type": "yoy_growth",
      "scale": null,
      "claimed_value_raw": "30.1%",
      "claimed_value": 30.1,
      "confidence": 1,
      "qualifiers": [],
      "quote_text": "TREMFYA delivered growth of 30.1%",
      "quote_end_char": 14213,
      "speaker_role": "management",
      "period": "Q2 2025",
      "comparison_period": "Q2 2024",
      "unit": "percent",
      "claim_id": "claim_035",
      "metric_type": "revenue",
      "is_approximate": false,
      "quote_start_char": 14180
    },
    {
      "qualifiers": [
        "declined by"
      ],
      "claim_type": "yoy_growth",
      "period": "Q2 2025",
      "quote_start_char": 14344,
      "claimed_value": 43.2,
      "speaker": "Darren Snellgrove",
      "is_approximate": false,
      "quote_end_char": 14370,
      "comparison_period": "Q2 2024",
      "confidence": 1,
      "metric_type": "revenue",
      "quote_text": "STELARRA declined by 43.2%",
      "claim_id": "claim_036",
      "unit": "percent",
      "speaker_role": "management",
      "metric_context": "STELARRA",
      "gaap_classification": "gaap",
      "claimed_value_raw": "43.2%",
      "scale": null
    },
    {
      "quote_end_char": 14782,
      "metric_context": "MedTech",
      "confidence": 1,
      "qualifiers": [],
      "speaker": "Darren Snellgrove",
      "gaap_classification": "gaap",
      "is_approximate": false,
      "scale": "billions",
      "comparison_period": null,
      "quote_start_char": 14736,
      "period": "Q2 2025",
      "claim_type": "absolute",
      "unit": "dollars",
      "claimed_value_raw": "$8.5 billion",
      "speaker_role": "management",
      "claimed_value": 8.5,
      "claim_id": "claim_037",
      "metric_type": "revenue",
      "quote_text": "Worldwide sales of $8.5 billion increased 6.1%"
    },
    {
      "quote_text": "We continued our strong investment in research and development, with $3.5 billion or approximately 15% of sales in Q2.",
      "quote_start_char": 17006,
      "comparison_period": null,
      "speaker": "Darren Snellgrove",
      "speaker_role": "management",
      "is_approximate": false,
      "period": "Q2 2025",
      "scale": "billions",
      "claim_id": "claim_038",
      "unit": "dollars",
      "confidence": 1,
      "claim_type": "absolute",
      "gaap_classification": "gaap",
      "claimed_value": 3.5,
      "qualifiers": [],
      "quote_end_char": 17124,
      "claimed_value_raw": "$3.5 billion",
      "metric_context": "Total",
      "metric_type": "research_and_development"
    },
    {
      "claimed_value_raw": "$6 billion",
      "period": "1H 2025",
      "is_approximate": false,
      "quote_start_char": 20271,
      "scale": "billions",
      "quote_end_char": 20336,
      "speaker": "John Reed",
      "gaap_classification": "unknown",
      "qualifiers": [
        "exceeded"
      ],
      "metric_type": "free_cash_flow",
      "unit": "dollars",
      "speaker_role": "management",
      "quote_text": "Free cash flow through the first half of 2025 exceeded $6 billion",
      "comparison_period": null,
      "claimed_value": 6,
      "confidence": 1,
      "claim_id": "claim_039",
      "claim_type": "absolute",
      "metric_context": "Total"
    },
    {
      "qualifiers": [
        "cash and marketable securities"
      ],
      "claim_type": "absolute",
      "metric_context": "Total",
      "is_approximate": false,
      "speaker_role": "management",
      "speaker": "John Reed",
      "quote_end_char": 20548,
      "quote_text": "We ended the second quarter with $19 billion of cash and marketable securities",
      "gaap_classification": "gaap",
      "unit": "dollars",
      "confidence": 1,
      "quote_start_char": 20470,
      "comparison_period": null,
      "period": "Q2 2025",
      "claimed_value_raw": "$19 billion",
      "metric_type": "other",
      "claim_id": "claim_040",
      "claimed_value": 19,
      "scale": "billions"
    },
    {
      "gaap_classification": "gaap",
      "unit": "dollars",
      "claimed_value": 51,
      "metric_context": "Total",
      "metric_type": "other",
      "quote_text": "and $51 billion of debt",
      "quote_start_char": 20549,
      "speaker": "John Reed",
      "period": "Q2 2025",
      "qualifiers": [
        "debt"
      ],
      "is_approximate": false,
      "confidence": 1,
      "claim_type": "absolute",
      "comparison_period": null,
      "claim_id": "claim_041",
      "quote_end_char": 20572,
      "speaker_role": "management",
      "scale": "billions",
      "claimed_value_raw": "$51 billion"
    },
    {
      "claim_type": "guidance",
      "claimed_value_raw": "$900 million",
      "claimed_value": 900,
      "speaker": "John Reed",
      "is_approximate": true,
      "quote_text": "we are increasing our operational sales guidance for the full year by approximately $900 million.",
      "confidence": 1,
      "unit": "dollars",
      "qualifiers": [
        "operational sales guidance",
        "increasing by approximately"
      ],
      "period": "FY 2025",
      "metric_context": "Total",
      "scale": "millions",
      "comparison_period": null,
      "quote_start_char": 21064,
      "claim_id": "claim_042",
      "gaap_classification": "non_gaap",
      "metric_type": "revenue",
      "quote_end_char": 21161,
      "speaker_role": "management"
    },
    {
      "claim_id": "claim_043",
      "unit": "dollars",
      "period": "FY 2025",
      "qualifiers": [
        "midpoint",
        "operational"
      ],
      "speaker": "John Reed",
      "speaker_role": "management",
      "quote_text": "with a midpoint of $92.9 billion or 4.8% (operational sales growth)",
      "metric_context": "Total",
      "is_approximate": false,
      "claim_type": "guidance",
      "metric_type": "revenue",
      "comparison_period": null,
      "claimed_value_raw": "$92.9 billion",
      "quote_start_char": null,
      "gaap_classification": "non_gaap",
      "claimed_value": 92.9,
      "confidence": 1,
      "quote_end_char": null,
      "scale": "billions"
    },
    {
      "speaker_role": "management",
      "confidence": 1,
      "gaap_classification": "gaap",
      "period": "FY 2025",
      "quote_text": "with a midpoint of $93.4 billion or 5.4% (reported sales growth)",
      "scale": "billions",
      "quote_end_char": null,
      "claimed_value_raw": "$93.4 billion",
      "speaker": "John Reed",
      "claim_type": "guidance",
      "metric_context": "Total",
      "claimed_value": 93.4,
      "quote_start_char": null,
      "claim_id": "claim_044",
      "comparison_period": null,
      "metric_type": "revenue",
      "is_approximate": false,
      "unit": "dollars",
      "qualifiers": [
        "reported sales growth",
        "midpoint"
      ]
    }
  ],
  "transcript_summary": "Johnson & Johnson reported robust Q2 2025 results with 4.6% operational sales growth and raised full-year guidance, driven by a diversified portfolio that successfully mitigated biosimilar competition for STELARRA.",
  "total_claims_found": 44,
  "ticker": "JNJ",
  "year": 2025,
  "quarter": 2,
  "extracted_at": "2026-02-13T11:50:21.152435"
}